2009 Archive


ANN ARBOR, Mich., October 9, 2009 — Lycera Corp., which is developing novel small-molecule pharmaceuticals to treat autoimmune diseases, today announced the appointments of Paul S. Changelian, Ph.D. and Peter L. Toogood, Ph.D. to the company’s drug development team. Dr. Changelian, previously director of inflammation biology at Pfizer, will serve as vice president of biology.… Read More

ANN ARBOR, Mich., August, 18 2009 — Lycera Corp. today announced the appointment of five accomplished scientists and clinicians to its Scientific Advisory Board. The company, which recently announced a $36 million Series A financing, is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. “Each of these… Read More

ANN ARBOR, Mich., July 29, 2009 —Lycera Corp. today announced that Robert Kamen, Ph.D., biotech consultant and past president of Abbott Bioresearch Center will join the company’s Board of Directors. Lycera, which recently announced a $36 million Series A financing, is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory… Read More

ANN ARBOR, Mich., April 16, 2009 — Lycera Corp. today announced it has closed a $36 million Series A financing. The company, which is developing novel small-molecule pharmaceuticals to treat autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, has received $10 million as a first tranche of the financing and will receive the… Read More